Myeloma Investment Fund Invests in KAHR’s Lead Immunotherapy Drug for Multiple Myeloma Treatment
The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation's (MMRF) venture philanthropy subsidiary, has invested in KAHR, a clinical-stage biotech company, to explore the potential of DSP107, KAHR's lead…
Continue Reading
Myeloma Investment Fund Invests in KAHR’s Lead Immunotherapy Drug for Multiple Myeloma Treatment